Muscle health.
A new dimension.
A botanical ingredient platform connecting nature-derived innovation, muscle-health science and everyday nutrition.
Nature-derived.
Purposefully developed.
ThymoTropin is Veos Pharma’s botanical muscle-health ingredient platform. Its commercial development brings together ingredient technology, branded consumer products and international partnership opportunities.
From botanical actives
to commercial products.
Thymol and carvacrol are central to the publicly described platform. Company-reported preclinical work explores myostatin regulation and TRPV3 signaling as part of its muscle-health and metabolic-development focus.
Veos Pharma’s commercial model connects the ingredient platform with finished formulations, distribution and partner-led product development.
Read the public partnering profile ↗Thyme. Oregano.
A molecular perspective.
Thymol and carvacrol are naturally occurring botanical monoterpenes. Published laboratory studies report that both can activate the TRPV3 ion channel.
Carvacrol
C₁₀H₁₄O · PubChem CID 10364TRPV3 viewer: mouse channel, PDB 6DVW, C-alpha backbone representation. Compound viewers: PubChem 3D conformers. Laboratory studies of isolated actives describe TRPV3 activation; the visual sequence does not show an experimentally established product-binding event or clinical effect.
A white powder.
A clear formulation conversation.
ThymoTropin is supplied as a white, water-soluble powder. Its ingredient format is part of the commercial discussion with product-development and formulation partners.
Muscle health.
Across life’s journeys.
Our platform development focuses on the role of muscle health in healthy aging, active living and weight-management nutrition.
Movement matters.
Healthy aging is a central area of focus for ThymoTropin. Our platform brings a botanical ingredient approach to conversations about muscle health, activity and everyday nutrition as people age.
Discuss the platform with our team ↗An early clinical signal.
A focused development story.
Veos Pharma’s public partnering profile describes a 60-day, open-label pilot in adults over 50. The measurements below are reported changes from that evaluation.
Serum myostatin
Company-reported decrease in the measured biomarker.
Arm circumference
Company-reported increase in the anthropometric measurement.
Pilot duration
Open-label evaluation in adults over 50.
Source: Veos Pharma’s public Halo partnering profile. Open-label pilot findings; arm circumference does not by itself establish a change in lean muscle mass. These data do not establish effectiveness alongside GLP-1 medicines.
View the public source ↗
BRANDED CONSUMER FORMULATIONThymoTropin.
Meet StroVia.
ThymoTropin is the ingredient platform. StroVia is the Canadian consumer formulation featuring ThymoTropin, bringing the platform into a branded Natural Health Product.
Veos Pharma connects ingredient development with product formulation and commercial distribution. Product information and availability are provided through the Canadian portfolio.
Explore Veos Pharma Canada ↗Build the next
product conversation.
Connect with Veos Pharma about ingredient supply, formulation opportunities, licensing and distribution.
Ingredient integration
Discuss the platform, format requirements and fit with your consumer-health product line.
Branded products
Explore consumer formulations, distribution channels and market-specific product information.
Territory partnerships
Discuss licensing and commercial opportunities with the Veos Pharma team.
A stronger platform.
A purposeful partnership.
Bring us your product idea or commercial opportunity.
Connect with our team ↗